Bio: An elected member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation, Dr. Chin is a world renowned cancer genomic scientist who had authored or co-authored over 200 peer-reviewed publications and spoken in over 300 national and international conferences including Tedmed. At Dana-Farber Cancer Institute where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard, Dr. Chin conducted research spanning mouse models of human cancers, cancer genomics, functional genomics and personalized medicine. Outside of her laboratory, Dr. Chin held multiple leadership positions in The Cancer Genome Atlas (TCGA) project in the U.S., including serving on the executive subcommittee and leading the development of Firehose pipeline as co-PI at the Broad Institute. Internationally, Dr. Chin has been active in the International Cancer Genome Consortium since its inception, currently sitting on the ICGC-ARGO Steering Committee and chairing its Phenomics Working Group. In 2011, Dr. Chin created the first Department of Genomic Medicine at MD Anderson Cancer Center with a mission to accelerate the translation of scientific advances and democratize the best care to patients outside of academic centers with technologies, data and AI analytics. In 2015, foreseeing the need for a new model to harness the potential of real-world health and health-related data, Dr. Chin launched the Institute for Health Transformation as the Chief Innovation Officer for University of Texas System. She designed and developed REDI (Real-world Education, early Detection and Intervention), an infrastructure platform for a connected health data and care delivery ecosystem. Collaborating with leaders from different industries, including PwC, AT&T and Walmart, engaging local stakeholders from federally qualified health center to community-based programs, Dr. Chin operationalized such an ecosystem in one of the poorest communities of South Texas to demonstrate how purposeful data sharing across public and private entities is feasible and how insight-driven actions can improve chronic disease management for a vulnerable population. A mother of three teenagers, Dr. Chin is an entrepreneur who has founded or co-founded cancer therapeutic, biomarker and AI companies.
Dr Lynda Chin
Associate Vice Chancellor & Chief Innovation Officer, The University of Texas System